Objective: S100A6 and S100A4, two of S100 protein family, have been suggested to be associated with cancer tumorigenesis and metastasis. The aim of this study was to evaluate the expression levels of S100A6 and S100A4 in matched samples of primary human colorectal adenocarcinomas (T), adjacent normal colorectal mucosa (N) and liver metastases (M). This gave us the advantage of directly comparing levels of S100A6 and S100A4 expression within the same genetic background. Methods: In matched samples of N, T and M from 10 colorectal adenocarcinoma patients, expressions of S100A6 and S100A4 were studied by Western blot and immunohistochemical analyses using specific antibodies against each protein. Results: The expression levels of S100A6 were significantly higher in T than in N (p < 0.05), while those of S100A4 showed no difference between T and N. There were no significant differences in the expression levels of S100A6 or S100A4 between M and T. Similar results were obtained by immunohistochemical analysis. Moreover, S100A6 was stained more intensely in invading fronts than in central portions of both T and M. Conclusions: The observed differential expression of S100A6 and S100A4 suggests that S100A6, rather than S100A4, is associated with human colorectal adenocarcinoma tumorigenesis and invasion/metastasis.

Keywords:
S100A6, S100A4, Human colorectal cancer
1.
Schäfer BW, Heizmann CW: The S100 family of EF-hand calcium-binding proteins: Functions and pathology. Trends Biochem Sci 1996;21:134–140.
2.
Barraclough R: Calcium-binding protein S100A4 in health and disease. Biochim Biophys Acta 1998;1448:190–199.
3.
Calabretta B, Battini R, Kaczmarek L, de Riel JK, Baserga R: Molecular cloning of the cDNA for a growth factor-inducible gene with strong homology to S-100, a calcium-binding protein. J Biol Chem 1986;261:12628–12632.
4.
Jackson-Grusby LL, Swiergiel J, Linzer DIH: A growth-related mRNA in cultured mouse cells encodes a placental calcium binding protein. Nucl Acids Res 1987;15:6677–6690.
5.
Tonini GP, Casalaro A, Cara A, Di Martino D: Inducible expression of calcyclin, a gene with strong homology to S-100 protein, during neuroblastoma cell differentiation and its prevalent expression in Schwann-like cell lines. Cancer Res 1991;51:1733–1737.
6.
Biesiada E, Chorazy M: Expression of ‘cell-cycle-dependent’ genes in regenerating rat liver. Cell Biol Int Rep 1988;12:483–492.
7.
Lewington AJP, Padanilam BJ, Hammerman MR: Induction of calcyclin after ischemic injury to rat kidney. Am J Physiol 1997;273:F380–F385.
8.
Timmons PM, Chan C-TJ, Rigby PWJ, Poirier F: The gene encoding the calcium binding protein calcyclin is expressed at sites of exocytosis in the mouse. J Cell Sci 1993;104:187–196.
9.
Okazaki K, Niki I, Iino S, Kobayashi S, Hidaka H: A role of calcyclin, a Ca2+-binding protein, on the Ca2+-dependent insulin release from the pancreatic β cell. J Biol Chem 1994;269:6149–6152.
10.
Guo X, Chambers AF, Parfett CLJ, Waterhouse P, Murphy LC, Reid RE, Graig AM, Edwards DR, Denhardt DT: Identification of a serum-inducible messenger RNA (5B10) as the mouse homologue of calcyclin: Tissue distribution and expression in metastatic, ras-transformed NIH 3T3 cells. Cell Growth Differ 1990;1:333–338.
11.
Weterman MAJ, Stoopen GM, van Muijen GNP, Kuznicki J, Ruiter DJ, Bloemers HPJ: Expression of calcyclin in human melanoma cell lines correlates with metastatic behavior in nude mice. Cancer Res 1992;52:1291–1296.
12.
Weterman MAJ, van Muijen GNP, Bloemers HPJ, Ruiter DJ: Expression of calcyclin in human melanocytic lesions. Cancer Res 1993;53:6061–6066.
13.
Ebralidze A, Tulchinsky E, Grigorian M, Afanasyeva A, Senin V, Revazova E, Lukanidin E: Isolation and characterization of a gene specifically expressed in different metastatic cells and whose deduced gene product has a high degree of homology to a Ca2+-binding protein family. Genes Dev 1989;3:1086–1093.
14.
Davies BR, Davies MPA, Gibbs FEM, Barraclough R, Rudland PS: Induction of the metastatic phenotype by transfection of a benign rat mammary epithelial cell line with the gene for p9Ka, a rat calcium-binding protein, but not with the oncogene EJ-ras-1. Oncogene 1993;8:999–1008.
15.
Maelandsmo GM, Hovig E, Skrede M, Engebraaten O, Flørenes VA, Myklebost O, Grigorian M, Lukanidin E, Scanlon KJ, Fodstad Ø: Reversal of the in vivo metastatic phenotype of human tumor cells by an anti-CAPL (mts1) ribozyme. Cancer Res 1996;56:5490–5498.
16.
Rudland PS, Platt-Higgins A, Renshaw C, West CR, Winstanley JHR, Robertson L, Barraclough R: Prognostic significance of the metastasis-inducing protein S100A4 (p9Ka) in human breast cancer. Cancer Res 2000;60:1595–1603.
17.
Platt-Higgins AM, Renshaw CA, West CR, Winstanley JHR, Rudland SDS, Barraclough R, Rudland PS: Comparison of the metastasis-inducing protein S100A4 (p9Ka) with other prognostic markers in human breast cancer. Int J Cancer 2000;89:198–208.
18.
Komatsu K, Andoh A, Ishiguro S, Suzuki N, Hunai H, Kobune-Fujiwara Y, Kameyama M, Miyoshi J, Akedo H, Nakamura H: Increased expression of S100A6 (calcyclin), a calcium-binding protein of S100 family, in human colorectal adenocarcinomas. Clin Cancer Res 2000;6:172–177.
19.
Komatsu K, Kobune-Fujiwara Y, Andoh A, Ishiguro S, Hunai H, Suzuki N, Kameyama M, Murata K, Miyoshi J, Akedo H, Tatsuta M, Nakamura H: Increased expression of S100A6 at the invading fronts of the primary lesion and liver metastasis in patients with colorectal adenocarcinoma. Brit J Cancer 2000;83:769–774.
20.
Berta GN, Ghezzo F, D’Avolio A, Zulian P, Carbone V, Racca S, Vercellino V, Di Carlo F: Enhancement of calcyclin gene RNA expression in squamous cell carcinoma of the oral mucosa, but not in benign lesions. J Oral Pathol Med 1997;26:206–210.
21.
Pedrocchi M, Schäfer BW, Mueller H, Eppenberger U, Heizmann CW: Expression of Ca2+-binding proteins of the S100 family in malignant human breast-cancer cell lines and biopsy samples. Int J Cancer 1994;57:684–690.
22.
Nikitenko LL, Lloyd BH, Rudland PS, Fear S, Barraclough R: Localisation by in situ hybridisation of S100A4 (p9Ka) mRNA in primary human breast tumour specimens. Int J Cancer 2000;86:219–228.
23.
Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1997;227:680–685.
24.
Matsudaira P: Sequence from picomole quantities of proteins electroblotted onto polyvinylidene difluoride membranes. J Biol Chem 1987;262:10035–10038.
25.
Schäfer BW, Wicki R, Engelkamp D, Mattei M-G, Heizmann CW: Isolation of a YAC clone convering a cluster of nine S-100 genes on human chromosome 1q21: Rationale for a new nomenclature of the S-100 calcium-binding protein family. Genomics 1995;25:638–643.
26.
Takenaga K, Nakanishi H, Wada K, Suzuki M, Matsuzaki O, Matsuura A, Endo H: Increased expression of S100A4, a metastasis-associated gene, in human colorectal adenocarcinomas. Clin Cancer Res 1997;3:2309–2316.
27.
Maelandsmo GM, Flørenes VA, Mellingsaeter T, Hovig E, Kerbel RS, Fodstad Ø: Differential expression patterns of S100A2, S100A4 and S100A6 during progression of human malignant melanoma. Int J Cancer 1997;74:464–469.
28.
Stulík J, Österreicher J, Koupilová K, Knízek J, Bures J, Jandík P, Langr F, Dedic K, Schäfer BW, Heizmann CW: Differential expression of the Ca2+ binding S100A6 protein in normal, preneoplastic and neoplastic colon mucosa. Eur J Cancer 2000;36:1050–1059.
29.
Cajot J-F, Sordat I, Silvestre T, Sordat B: Differntial display cloning identifies motility-related protein (MRP1/CD9) as highly expressed in primary compared to metastatic human colon carcinoma cells. Cancer Res 1997;57:2593–2597.
30.
Ayaki M, Komatsu K, Mutsuko M, Murata K, Kameyama M, Ishiguro S, Miyoshi J, Tatsuta M, Nakamura H: Reduced expression of focal adhesion kinase in liver metastases compared to matched primary human colorectal adenocarcinomas. Clin Cancer Res 2001;7:3106–3112.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.